# OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

> **NCT00902837** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research GmbH & Co KG** · enrollment: 181 (actual)

## Conditions studied

- Chronic Osteoarthritis

## Interventions

- **DRUG:** Oxycodone naloxone prolonged release tablets (OXN)
- **DRUG:** oxycodone prolonged release tablet
- **DRUG:** oxycodone naloxone tablet

## Key facts

- **NCT ID:** NCT00902837
- **Lead sponsor:** Mundipharma Research GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-04
- **Final completion:** 2010-07
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2018-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902837, "OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00902837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*